filmov
tv
Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC
Показать описание
Scott Kopetz, MD, PhD, FACP, discusses the rationale for the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.
OncLive
cancer
oncology
Рекомендации по теме
0:01:11
Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC
0:01:54
Dr. Kopetz on the Rationale and Primary Endpoints of the BEACON CRC Study in mCRC
0:01:34
Dr. Kopetz on the Biology of Right- Versus Left-Sided CRC
0:01:09
Dr. Kopetz on Updated Data From BEACON CRC Study in BRAF V600E–Mutant CRC
0:00:54
Dr. Kopetz on Safety Data From BEACON CRC Trial in BRAF V600E-Mutant mCRC
0:32:43
Colorectal Cancer and Immunotherapy with Dr. Scott Kopetz
0:01:17
Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600–Mutant Melanoma
0:02:21
Meet gastrointestinal medical oncologist Scott Kopetz, M.D., Ph.D.
0:01:46
Bringing CTCs to the forefront of therapeutics
0:36:11
Dr. Scott Kopetz from MD Anderson Cancer Center discusses the BREAKWATER trial with Dr. Manju George
0:59:06
In this #DocTalk, Dr Scott Kopetz from MD Anderson discusses Minimal Residual Disease in CRC
0:00:38
Scott Kopetz, MD, PhD, FACP, discusses the incidence of BRAF mutation in CRC patients
0:01:01
Scott Kopetz, MD, PhD, FACP, regarding molecular profile matching in trials with mCRC patients
0:59:38
Dr Scott Kopetz Deputy Chair, GI Med Oncology MD Anderson discusses KRAS-directed therapies for CRC
0:01:35
Scott Kopetz, MD, shares updates from the BEACON trial in BRAF-mutant colorectal cancer
0:00:58
Scott Kopetz, MD, PhD, FACP, tells us about the outcomes of Checkmate 142 in mCRC patients
0:01:06
Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRC
0:01:06
Dr. Matulonis Discusses Rationale of QUADRA Trial
1:13:25
Prof Eric Van Cutsem, MD & Scott Kopetz, MD discuss Colorectal Cancer: https://bit.ly/3vfphKP
0:01:59
Scott Kopetz, MD, PhD, FACP, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC
0:57:20
Winship Grand Rounds: March 24, 2021 - Scott Kopetz, MD, PhD, FACP
0:09:53
Dose Modification Rationale in Advanced Pancreatic Cancer
0:01:32
Dr. Flaherty on the Rationale to Explore Triplet Therapy in BRAF V600E-Mutant Melanoma
0:22:10
Novel Agents and Targets in Colorectal Cancer